expression profiling data of CLB-GA neuroblastoma cells upon TAE-684, Crizotinib, X-396, LDK378, Trametinib, BEZ-235 and Vandetanib

·发布 2015年5月4日 ·更新 2015年5月4日

样本数

实验数

芯片平台

相关文献

实验描述

Treatment of the CLB-GA cell line with complementary ALK, MEK, PI3K/mTOR or RET inhibitors (and DMSO (VWR) as control) was performed in duplicate for each drug using the GI50 concentrations (see further): 0.5ë_M Crizotinib (Pfizer/Sigma-Aldrich); 0.06ë_M X-396 (VWR); 0.2ë_M LDK378 (Hoelzel Biotech); 0.05uM Trametinib (SelleckChem); 0.5ë_M BEZ-235 (SelleckChem); 9.5ë_M Vandetanib (SelleckChem). Cells were collected at 6h following treatment and further profiled. The selected inhibitor concentrations were used based on determined GI50 values. For generation of gene expression time series following ALK inhibition, CLB-GA cells were treated with 0.3uM TAE-684 (and DMSO as control treatment) and RNA was harvested at 0 ‰ÛÒ 10‰۪ ‰ÛÒ 30‰۪ ‰ÛÒ 60‰۪ ‰ÛÒ 120‰۪ ‰ÛÒ 240‰۪ ‰ÛÒ 360‰۪ time points. Samples were labeled and hybridised to the Sureprint G3 human GE or G3 Mouse GE 8x60K microarrays (Agilent Technologies), according to the manufacturer‰۪s guidelines and starting from 200 ng of RNA.

参考文献

Upregulation of MAPK negative feedback regulators and RET in mutant ALK neuroblastoma: implications for targeted treatment

Irina Lambertz1*, Candy Kumps1*, Shana Claeys1, Sven Lindner2, Anneleen Beckers1, Els Janssens1, Daniel R. Carter3, Alex Cazes4, Belamy B. Cheung3, Marilena De Mariano5, An De Bondt6, Sara De Brouwer1, Olivier Delattre4, Jay Gibbons7, Isabelle Janoueix4, Genevi̬ve Laureys8, Chris Liang7, Glenn M. Marchall3, Michael Porcu9, Junko Takita10, David Camacho Trujillo1, Ilse Van Den Wyngaert6, Nadine Van Roy1, Alan Van Goethem1, Tom Van Maerken1, Piotr Zabrocki9, Jan Cools9, Johannes H. Schulte2,11,12,13,14, Jorge Vialard15, Frank Speleman1**$, Katleen De Preter1**

PMID: 25805801

芯片平台

A-MEXP-2102

Agilent 028004 SurePrint G3 Human GE 8x60K Microarray（48 例）

样本属性

cell line

CLB-GA

filename

US45103088_252800415825_S01_GE1_105_Dec08_1_1.txt, US45103088_252800415825_S01_GE1_105_Dec08_1_2.txt, US45103088_252800415825_S01_GE1_105_Dec08_1_3.txt, US45103088_252800415825_S01_GE1_105_Dec08_1_4.txt, US45103088_252800415825_S01_GE1_105_Dec08_2_1.txt, US45103088_252800415825_S01_GE1_105_Dec08_2_2.txt, US45103088_252800415825_S01_GE1_105_Dec08_2_3.txt, US45103088_252800415825_S01_GE1_105_Dec08_2_4.txt, US45103088_252800415826_S01_GE1_105_Dec08_1_1.txt, US45103088_252800415826_S01_GE1_105_Dec08_1_2.txt, US45103088_252800415826_S01_GE1_105_Dec08_1_3.txt, US45103088_252800415826_S01_GE1_105_Dec08_1_4.txt, US45103088_252800415826_S01_GE1_105_Dec08_2_1.txt, US45103088_252800415826_S01_GE1_105_Dec08_2_2.txt, US45103088_252800415826_S01_GE1_105_Dec08_2_3.txt, US45103088_252800415826_S01_GE1_105_Dec08_2_4.txt, US45103088_252800415836_S01_GE1_105_Dec08_1_1.txt, US45103088_252800415836_S01_GE1_105_Dec08_1_2.txt, US45103088_252800415836_S01_GE1_105_Dec08_1_3.txt, US45103088_252800415836_S01_GE1_105_Dec08_1_4.txt, US45103088_252800415836_S01_GE1_105_Dec08_2_1.txt, US45103088_252800415836_S01_GE1_105_Dec08_2_2.txt, US45103088_252800415836_S01_GE1_105_Dec08_2_3.txt, US45103088_252800415836_S01_GE1_105_Dec08_2_4.txt, US45103088_252800419704_S01_GE1_105_Dec08_1_1.txt, US45103088_252800419704_S01_GE1_105_Dec08_1_2.txt, US45103088_252800419704_S01_GE1_105_Dec08_1_3.txt, US45103088_252800419704_S01_GE1_105_Dec08_1_4.txt, US45103088_252800419704_S01_GE1_105_Dec08_2_1.txt, US45103088_252800419704_S01_GE1_105_Dec08_2_2.txt, US45103088_252800419704_S01_GE1_105_Dec08_2_3.txt, US45103088_252800419704_S01_GE1_105_Dec08_2_4.txt, US45103088_252800419753_S01_GE1_105_Dec08_1_1.txt, US45103088_252800419753_S01_GE1_105_Dec08_1_2.txt, US45103088_252800419753_S01_GE1_105_Dec08_1_3.txt, US45103088_252800419753_S01_GE1_105_Dec08_1_4.txt, US45103088_252800419753_S01_GE1_105_Dec08_2_1.txt, US45103088_252800419753_S01_GE1_105_Dec08_2_2.txt, US45103088_252800419753_S01_GE1_105_Dec08_2_3.txt, US45103088_252800419753_S01_GE1_105_Dec08_2_4.txt, US45103088_252800419760_S01_GE1_105_Dec08_2_1.txt, US45103088_252800419760_S01_GE1_105_Dec08_2_2.txt, US45103088_252800419760_S01_GE1_105_Dec08_2_3.txt, US45103088_252800419760_S01_GE1_105_Dec08_2_4.txt, US45103088_252800420868_S01_GE1_105_Dec08_2_1.txt, US45103088_252800420868_S01_GE1_105_Dec08_2_2.txt, US45103088_252800420868_S01_GE1_105_Dec08_2_3.txt, US45103088_252800420868_S01_GE1_105_Dec08_2_4.txt

organism

homo sapiens

实验信息

登记号

E-MTAB-3206

实验类型

transcription profiling by array

物种

homo sapiens

发布日期

2015年5月4日

更新日期

2015年5月4日

提交者

Katleen De Preter

外部链接

ArrayExpress 原始页

分析服务

expression profiling data of CLB-GA neuroblastoma cells upon TAE-684, Crizotinib, X-396, LDK378, Trametinib, BEZ-235 and Vandetanib

联系地址

微信公众号